13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
45 檔
22.7%
At the close of Q3 2024, Prosight Management, LP disclosed equity holdings valued at approximately $580.4M, spread across 45 reported holdings.
Prosight Management, LP executed strategic sector rebalancing during Q3 2024, establishing 16 new positions while fully exiting 17 holdings and trimming 12 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Adc Therapeutics SA | Stock-Other | 7.47% | -3.66% | +0.69% | |
| 2 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 7.29% | +2.93% | -23.79% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.81% | — | +35.85% | |
| 4 | ABCL | Abcellera Biologics Inc | Stock-Other | 5.81% | — | +285.93% | |
| 5 | MGTX | MeiraGTx Holdings plc | Stock-Other | 5.03% | -3.52% | +12.59% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.89% | -0.82% | EXIT | |
| 7 | STTK | Shattuck Labs Inc | Stock-Other | 4.88% | +1.84% | +21.60% | |
| 8 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.47% | — | +47.97% | |
| 9 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 4.40% | — | -2.59% | |
| 10 | MCK | Mckesson CORP | Stock-Healthcare | 4.36% | — | — | |
| 11 | KURA | Kura Oncology Inc | Stock-Other | 3.39% | -0.66% | +11.94% | |
| 12 | SDGR | Schrodinger Inc | Stock-Other | 3.20% | -0.95% | EXIT | |
| 13 | ZYME | Zymeworks Inc | Stock-Other | 2.83% | +0.83% | -22.24% | |
| 14 | ACCDUSD | Accolade Inc | Stock-Other | 2.65% | — | +88.09% | |
| 15 | DXCM | Dexcom Inc | Stock-Healthcare | 2.64% | — | +224.43% | |
| 16 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.62% | +1.57% | +0.46% | |
| 17 | IMVT | Immunovant Inc | Stock-Other | 2.60% | -0.72% | EXIT | |
| 18 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.50% | — | -16.22% | |
| 19 | JANX | Janux Therapeutics Inc | Stock-Other | 2.29% | +1.98% | — | |
| 20 | PRTA | Prothena Corporation plc | Stock-Other | 1.99% | — | +68.50% | |
| 21 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.76% | — | +129.63% | |
| 22 | ✓ | Ishares Tr | Stock-Other | 1.58% | — | — | |
| 23 | ERAS | Erasca Inc | Stock-Other | 1.33% | — | -27.85% | |
| 24 | HAE | Haemonetics Corp/mass | Stock-Other | 1.29% | — | — | |
| 25 | LIVN | LivaNova PLC | Stock-Other | 1.16% | — | — | |
| 26 | COGT | Cogent Biosciences Inc | Stock-Other | 1.09% | — | -17.83% | |
| 27 | ✓ | Cassava Sciences Inc | Stock-Other | 1.08% | — | — | |
| 28 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.07% | — | — | |
| 29 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.03% | -0.16% | +103.99% | |
| 30 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.88% | — | — | |
| 31 | SGHT | Sight Sciences Inc | Stock-Other | 0.82% | — | — | |
| 32 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.75% | -0.24% | EXIT | |
| 33 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.72% | +0.01% | — | |
| 34 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.66% | -0.02% | — | |
| 35 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.44% | — | +20.01% | |
| 36 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.43% | — | — | |
| 37 | ✓ | Vincerx Pharma Inc | Stock-Other | 0.39% | — | -11.33% | |
| 38 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.32% | +0.11% | +40.44% | |
| 39 | ✓ | Corvel CORP | Stock-Other | 0.23% | — | — | |
| 40 | SEM | Select Medical Holdings CORP | Stock-Other | 0.22% | — | — | |
| 41 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.21% | — | -32.17% | |
| 42 | IMNM | Immunome Inc | Stock-Other | 0.14% | — | -39.79% | |
| 43 | IMRX | Immuneering CORP - Class A | Stock-Other | 0.12% | -0.08% | -65.45% | |
| 44 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.09% | — | — | |
| 45 | ✓ | Shattuck Labs Inc | Stock-Other | 0.07% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MCK | Mckesson CORP | +4.4% | NEW | New buy |
| 2 | ABCL | Abcellera Biologics Inc | +3.7% | +285.93% | Add |
| 3 | JANX | Janux Therapeutics Inc | +2.3% | NEW | New buy |
| 4 | ✓ | Ishares Tr | +1.6% | NEW | New buy |
| 5 | HAE | Haemonetics Corp/mass | +1.3% | NEW | New buy |
| 6 | MIRM | Mirum Pharmaceuticals Inc | +1.3% | +47.97% | Add |
| 7 | LIVN | LivaNova PLC | +1.2% | NEW | New buy |
| 8 | ✓ | Cassava Sciences Inc | +1.1% | NEW | New buy |
| 9 | SDGR | Schrodinger Inc | +1.1% | +89.57% | Add |
| 10 | 2655787D | Blueprint Medicines CORP | +1.1% | NEW | New buy |
| 11 | ACCDUSD | Accolade Inc | +1.1% | +88.09% | Add |
| 12 | DXCM | Dexcom Inc | +1% | +224.43% | Add |
| 13 | CTMX | Cytomx Therapeutics Inc | +0.9% | NEW | New buy |
| 14 | SGHT | Sight Sciences Inc | +0.8% | NEW | New buy |
| 15 | BBIO | Bridgebio Pharma Inc | +0.8% | +35.85% | Add |
| 16 | RCKT | Rocket Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 17 | TECX | Tectonic Therapeutic Inc | +0.7% | +103.99% | Add |
| 18 | CRBP | Corbus Pharmaceuticals Holdi | +0.7% | NEW | New buy |
| 19 | NBIX | Neurocrine Biosciences Inc | +0.7% | +129.63% | Add |
| 20 | MRVI | Maravai Lifesciences Hldgs-a | +0.4% | NEW | New buy |
| 21 | ✓ | Corvel CORP | +0.2% | NEW | New buy |
| 22 | PRTA | Prothena Corporation plc | +0.2% | +68.50% | Add |
| 23 | SEM | Select Medical Holdings CORP | +0.2% | NEW | New buy |
| 24 | RNTX | Rein Therapeutics Inc | +0.1% | +40.44% | Add |
| 25 | ACHC | Acadia Healthcare Co Inc | +0.1% | NEW | New buy |
| 26 | ✓ | Shattuck Labs Inc | +0.1% | NEW | New buy |
| 27 | IMVT | Immunovant Inc | 0% | +13.85% | Add |
| 28 | ✓ | Mural Oncology Pub LTD Co | 0% | +20.01% | Add |
| 29 | ✓ | 0% | EXIT | Sold out | |
| 30 | OVID | Ovid Therapeutics Inc | 0% | -32.17% | Trim |
| 31 | IMRX | Immuneering CORP - Class A | -0.1% | -65.45% | Trim |
| 32 | IMNM | Immunome Inc | -0.1% | -39.79% | Trim |
| 33 | ZYME | Zymeworks Inc | -0.2% | -22.24% | Trim |
| 34 | BMEA | Biomea Fusion Inc | -0.2% | EXIT | Sold out |
| 35 | COGT | Cogent Biosciences Inc | -0.2% | -17.83% | Trim |
| 36 | ✓ | Vincerx Pharma Inc | -0.2% | -11.33% | Trim |
| 37 | TXG | 10x Genomics Inc-class A | -0.3% | EXIT | Sold out |
| 38 | LENZ | Lenz Therapeutics Inc | -0.3% | EXIT | Sold out |
| 39 | ADUS | Addus Homecare CORP | -0.4% | EXIT | Sold out |
| 40 | MGTX | MeiraGTx Holdings plc | -0.5% | +12.59% | Add |
| 41 | KURA | Kura Oncology Inc | -0.5% | +11.94% | Add |
| 42 | PRVA | Privia Health Group Inc | -0.5% | EXIT | Sold out |
| 43 | STTK | Shattuck Labs Inc | -0.5% | +21.60% | Add |
| 44 | UHS | Universal Health Services-b | -0.5% | EXIT | Sold out |
| 45 | FNAUSD | Paragon 28 Inc | -0.5% | EXIT | Sold out |
| 46 | INSP | Inspire Medical Systems Inc | -0.6% | EXIT | Sold out |
| 47 | ERAS | Erasca Inc | -0.6% | -27.85% | Trim |
| 48 | CVS | Cvs Health CORP | -0.7% | EXIT | Sold out |
| 49 | MDT | Medtronic plc | -0.7% | EXIT | Sold out |
| 50 | BCRX | Biocryst Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 45 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ADC THERAPEUTICS SA, LKFT, BBIO) accounted for 22.7% of total reported equity market value during Q3 2024.
Top New Position Initiated
MCK
市值: $17.7M
Top Position Liquidated / Trimmed
KELYA
前期市值: $10.5M
During Q3 2024, Prosight Management, LP's top holdings by market value included ADC THERAPEUTICS SA (7.5%)、LKFT (7.3%)、BBIO (6.8%). The largest single position, ADC THERAPEUTICS SA, represented 7.5% of total portfolio value.
In Q3 2024, Prosight Management, LP made 62 total portfolio adjustments, initiating 16 new buys, adding to 17 positions, trimming 12 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.